Patents by Inventor Newman Yeilding

Newman Yeilding has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of treating psoriasis with anti-IL23 specific antibody
    Patent number: 11208474
    Abstract: A method of treating psoriasis in a patient previously treated with and determined to be an inadequate responder to an IL-12/23p40 antibody by administering an IL-23 specific antibody, e.g., guselkumab, in a safe and effective amount and the patient achieves PASI75, PASI90, PASI100 or IGA 0 or 1 score as measured 16, 24, 32, 40 and 48 weeks after initial treatment.
    Type: Grant
    Filed: November 15, 2017
    Date of Patent: December 28, 2021
    Assignee: JANSSEN BIOTECH, INC.
    Inventors: Dennis Fitzgerald, Newman Yeilding, Jay Siegel
  • Method of treating psoriatic arthritis with increased interval dosing of anti-IL12/23 antibody
    Patent number: 11197913
    Abstract: A method of treating an IL-12/23-related disease in a patient using an increasing dosing interval, comprises increasing the dosing interval of IL-12/IL-23 antibody to a patient, wherein the antibody is administered initially and after 4 weeks, after 16 weeks and after 28 weeks, and increasing the dosing interval after 28 weeks to an increased interval, e.g., every 16, 20 or 24 weeks.
    Type: Grant
    Filed: August 14, 2020
    Date of Patent: December 14, 2021
    Assignee: JANSSEN BIOTECH, INC.
    Inventors: Marc Chevrier, Kamyar Farahi, Newman Yeilding
  • Method of Treating Psoriasis with Anti-IL23 Specific Antibody
    Publication number: 20210179703
    Abstract: A method of treating psoriasis in a patient previously treated with and determined to be an inadequate responder to an IL-12/23p40 antibody by administering an IL-23 specific antibody, e.g., guselkumab, in a safe and effective amount and the patient achieves PASI75, PASI90, PASI100 or IGA 0 or 1 score as measured 16, 24, 32, 40 and 48 weeks after initial treatment.
    Type: Application
    Filed: February 1, 2021
    Publication date: June 17, 2021
    Inventors: Dennis Fitzgerald, Jay Siegel, Newman Yeilding
  • Method of Treating Psoriatic Arthritis with Increased Interval Dosing of Anti-IL12/23 Antibody
    Publication number: 20200384081
    Abstract: A method of treating an IL-12/23-related disease in a patient using an increasing dosing interval, comprises increasing the dosing interval of IL-12/IL-23 antibody to a patient, wherein the antibody is administered initially and after 4 weeks, after 16 weeks and after 28 weeks, and increasing the dosing interval after 28 weeks to an increased interval, e.g., every 16, 20 or 24 weeks.
    Type: Application
    Filed: August 14, 2020
    Publication date: December 10, 2020
    Inventors: Marc Chevrier, Kamyar Farahi, Newman Yeilding
  • Method of treating psoriasis with increased interval dosing of anti-IL12/23 antibody
    Patent number: 10765724
    Abstract: A method of treating an IL-12/23-related disease in a patient using an increasing dosing interval, comprises increasing the dosing interval of IL-12/IL-23 antibody to a patient, wherein the antibody is administered initially and after 4 weeks, after 16 weeks and after 28 weeks, and increasing the dosing interval after 28 weeks to an increased interval, e.g., every 16, 20 or 24 weeks.
    Type: Grant
    Filed: March 28, 2017
    Date of Patent: September 8, 2020
    Assignee: Janssen Biotech, Inc.
    Inventors: Marc Chevrier, Kamyar Farahi, Newman Yeilding
  • Method of Treating Psoriasis with Increased Interval Dosing of Anti-IL12/23 Antibody
    Publication number: 20180036379
    Abstract: A method of treating an IL-12/23-related disease in a patient using an increasing dosing interval, comprises increasing the dosing interval of IL-12/IL-23 antibody to a patient, wherein the antibody is administered initially and after 4 weeks, after 16 weeks and after 28 weeks, and increasing the dosing interval after 28 weeks to an increased interval, e.g., every 16, 20 or 24 weeks.
    Type: Application
    Filed: March 28, 2017
    Publication date: February 8, 2018
    Inventors: Marc Chevrier, Kamyar Farahi, Newman Yeilding